Caroline Silva

Prof. Dr. Caroline Silva

Ribeirao Preto Medical School - FMRP/USP, Ribeirão Prêto, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Food & Function
Verified
Journal Article
Open access
PDF file
MRMarina Rodrigues
Marina Rodrigues
Caroline SilvaCaroline Silva
Caroline Silva
AJAnderson Gregorio Joaquim
Anderson Gregorio Joaquim
CMCássia Dias Machado
Cássia Dias Machado
LRLeandra Náira Zambelli Ramalho
Leandra Náira Zambelli Ramalho
VSVivian Marques Miguel Suen
Vivian Marques Miguel Suen
Due to the increase in the prevalence of obesity, new therapies have emerged and eugenol has been shown to be beneficial in metabolic changes and gut microbiota. This study aimed to investigate the effects of eugenol on gut microbiota, hepatic lipid accumulation, body weight, adipose tissue weight, lipid and glycemic profile in mice fed a high-fat diet. Forty C57BL/6 male mice were divided into standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE) and high-fat diet with eugenol (HFDE). The dose used of eugenol was 500 mg kg−1 for 8 weeks. Eugenol did not prevent weight gain, but it was effective in preventing hepatic lipid accumulation evidenced by the presence of fat droplets in the HFD group and absence in the HFDE group. An improvement in the gut microbiota profile was observed, proved by an increase in the Actinobacteria phylum in the treated groups and a reduction of Proteobacteria phylum in the HFDE group. Despite not preventing weight gain, eugenol appeared to have a protective effect on hepatic lipid accumulation and beneficially modulate the gut microbiota in mice fed with HFD.

2 January 2019 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
Caroline SilvaCaroline Silva
Caroline Silva
PFPriscila Giacomo Fassini
Priscila Giacomo Fassini
LRLeandra Náira Zambelli Ramalho
Leandra Náira Zambelli Ramalho
ECEdemilson Cardoso da Conceição
Edemilson Cardoso da Conceição
AZAline José Coelho Moreira Zordan
Aline José Coelho Moreira Zordan
VSVivian Marques Miguel Suen
Vivian Marques Miguel Suen

1 March 2022 in Nutrición Hospitalaria
Verified
Journal Article
Open access
Caroline SilvaCaroline Silva
Caroline Silva
BMBruna Lopes Meghelli
Bruna Lopes Meghelli
AJAnderson Gregorio Joaquim
Anderson Gregorio Joaquim
GRGraziela Nogueira de Almeida Ribeiro
Graziela Nogueira de Almeida Ribeiro
WSWilson Salgado-Júnior
Wilson Salgado-Júnior
VSVivian Marques Miguel Suen
Vivian Marques Miguel Suen
Background: reduced cognitive performance has been observed in patients with severe obesity. Bariatric surgery and subsequent adipose tissue loss seem to affect cognitive functioning positively; however, improvement predictors are not well established. Aim: to evaluate the cognitive performance and the nutritional status of patients with severe obesity 6-month after bariatric surgery. Methods: we assessed the neuropsychological performance of 22 patients with obesity (body mass index: similar to 42.9 kg/m(2)). The nutritional evaluation consisted of the routine tests performed in the baseline and postoperative periods. Lastly, we calculated the correlation between neuropsychological assessment results and blood biomarkers. Results: the patients did not present cognitive impairment in the preoperative assessment, but performed below the standard range. The patients underwent significant weight loss after 6 months from surgery (similar to 22 kg), with a change in obesity class III to I. Also, the patients presented a significant improvement in attention, mental flexibility, inhibitory control, and processing speed. Additionally, we observed a significant improvement in serum folic acid (108 %), gamma-glutamyl transferase (-41 %), uric acid (-32 %), ferritin (-28 %), triglycerides (-19 %), and high-density lipoprotein (9 %). Lastly, we found a moderate positive correlation between processing speed and body weight (r = 0.46), gamma-glutamyl transferase (r = 0.54), and total protein and mental flexibility (r = 0.75). Conclusion: bariatric surgery promoted significant weight loss and improved attention, mental flexibility, processing speed, and several nutritional biomarkers. Nevertheless, the surgery had limited effects on other cognitive functions such as short- and long-term memory and language.

28 January 2019 in Journal of Food and Nutrition Research
Verified
Journal Article
Open access
PDF file
ACAna Carolina Campi Cansian
Ana Carolina Campi Cansian
Caroline SilvaCaroline Silva
Caroline Silva
AJAnderson Gregorio Joaquim
Anderson Gregorio Joaquim
CMCassia Dias Machado
Cassia Dias Machado
DCDaniela Carlos
Daniela Carlos
VSVivian Marques Miguel Suen
Vivian Marques Miguel Suen
We hypothesized that capsinoids supplementation, a bioactive vanillylamines isolated from chili peppers, would exert protective effects against high-fat diet -induced weight gain via regulation of lipid, glucose and insulin profile. To test our hypothesis, twenty-four male Wistar rats were fed a standard diet, standard diet with capsinoids, high-fat diet and high-fat diet with capsinoids for 6 weeks. Capsinoids dose was 0.18 mg/kg/d. During the experiment, body weight and food intake were evaluated weekly and biochemical analyses were performed at the end of the experimental period. Only high-fat diet with capsinoids presented lower total food intake as compared to standard diet with capsinoids group (~35%). Nevertheless, there were no significant differences in weight gain between the groups. Capsinoids supplementation did not prevent retroperitoneal and epididymal fat gain on high-fat diet with capsinoids, as well did not change brown fat and liver weight. Moreover, no statistical difference was observed for high-fat diet or capsinoids supplementation on blood glucose, insulin and lipid profile. In conclusion, these results suggest that capsinoids supplementation in obesity experimental model of Wistar rats, has limited effects to prevent weight and fat gain, as well as do not regulate metabolic profile.

27 September 2018
Verified
Conference Paper
Open access
CMCássia Dias Machado
Cássia Dias Machado
Caroline SilvaCaroline Silva
Caroline Silva
MRMarina Rodrigues
Marina Rodrigues
VSVivian Marques Miguel Suen
Vivian Marques Miguel Suen
Introdução: Obesidade é uma doença crônica e multifatorial que, atinge mais de um milhão de indivíduos mundialmente, sendo determinada pelo excesso relativo ou absoluto das reservas corporais de gordura. Diante do aumento de sua prevalência, inúmeros tratamentos têm surgido e dentre eles, grande interesse pelo potencial dos fitoterápicos. Dentre as espécies de vegetais estudadas, tem-se o Cravo da Índia (Syzygium aromaticum) com possível ação na prevenção da obesidade. Objetivo: Avaliar o efeito do extrato etanólico do cravo da índia no controle do ganho de peso e gorduras corporais em camundongos C57BL/6 alimentados com dieta hiperlipídica. Metodologia: Foram utilizados 48 camundongos machos, divididos em 4 grupos de 12 animais cada: dieta padrão (DP), dieta padrão com cravo (DPC), dieta hiperlipídica (DH) e dieta hiperlipídica com cravo (DHC) e todos em condições controladas de luminosidade e temperatura . Os animais do grupo dieta padrão foram alimentados com uma ração padrão ad libitum (nuvilab) e os do grupo dieta hiperlipídica foram alimentados com ração hiperlipídica durante 8 semanas. a suplementação de extrato etanólico de cravo foi feita via gavagem na dose de 250 mg/kg/dia. o peso e a ingestão foram aferidos semanalmente. Resultados: Observou-se que nos grupos DP e DPC, o peso e a ingestão se diferiram durante todo o tratamento, sendo o grupo DP o que apresentou maior ingestão, logo, ganhando mais peso quando comparado ao DPC. nos grupos de dieta hiperlipídica, observa-se que a dieta foi eficiente para o ganho de peso, pois ao comparar com os grupos de dieta padrão, esses grupos (DH e DHC) foram os que tiveram maior ganho de peso, apesar do grupo DP ter apresentado maior ingestão. o grupo DPC teve uma menor ingestão e um menor peso durante todo o tratamento quando comparado ao grupo DHC, evidenciando assim que o extrato etanólico de cravo não teve nenhum efeito relacionado ao peso dos animais. em relação ao peso das gorduras (retroperitoneal, epididimal), essas não se diferiram entre os grupos de dieta padrão e nos grupos de dieta hiperlipídica foram maiores no grupo suplementado. Quanto a gordura marrom, essa também não se diferiu nos grupos de dieta padrão, porém, embora de forma não significativa, apresentou uma. Conclusão: a adição de extrato etanólico de cravo não teve nenhum efeito relacionado a prevenção de ganho de peso e de gordura corporal, uma vez que o ganho de peso foi compatível com a ingestão de todos os grupos.

1 January 2025 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
ACAldrina Laura da Silva Costa
Aldrina Laura da Silva Costa
JSJosé Ernesto dos Santos
José Ernesto dos Santos
WJWilson Salgado Jr
Wilson Salgado Jr
Caroline SilvaCaroline Silva
Caroline Silva
LBLetícia Bizari
Letícia Bizari
VSVivian Marques Miguel Suen
Vivian Marques Miguel Suen
SUMMARY OBJECTIVE: The aim of this study was to investigate polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene and compare disease severity in familial hypercholesterolemia participants with and without these polymorphisms. METHODS: Fifty patients were included in this observational, cross-sectional study of primary data collection between June 2014 and June 2015 at Clinics Hospital of Ribeirão Preto Medical School/University of São Paulo Inclusion criteria for the study included individuals with an low-density lipoprotein cholesterol level ≥190 mg/dL, based on Dutch make early diagnosis prevent early death criteria for familial hypercholesterolemia. Patients with kidney disease, liver failure, a triglyceride level ≥300 mg/dL, or hypothyroidism were excluded. Gene analysis was performed using the high-resolution melting method. deoxyribonucleic acid samples with detected changes were sequenced to identify polymorphisms. Lipid profile, body mass index, history of cardiovascular events, gender, and statin use were compared between participants with and without polymorphisms. RESULTS: Of the 50 patients, 14 carried proprotein convertase subtilisin/kexin type 9 polymorphisms. Familial hypercholesterolemia was not associated with these polymorphisms in this cohort. As gene expression was not assessed, no conclusions can be drawn regarding functional effects. Six patients (four in the polymorphism group and two in the non-polymorphism group) reported cardiovascular events. The significantly higher occurrence of these events in the polymorphism group suggests a possible association between the presence of proprotein convertase subtilisin/kexin type 9 polymorphisms and an increased cardiovascular risk. CONCLUSION: Benign variants were identified in the proprotein convertase subtilisin/kexin type 9 gene, with no pathogenic alterations detected. Despite the significantly higher number of participants with a history of cardiovascular events in the polymorphism group, these data do not support a direct, causal association between these polymorphisms and an increased cardiovascular risk.